Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists
A Non-Interventional Study on Type 2 Diabetes Mellitus Patient's Characteristics and Management by General Practitioners and Endocrinologists in the Russian Population (THESEUS)
This is a multi-centre observational, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with type 2 diabetes mellitus (T2DM) initiated with dapagliflozin by general practitioners (GPs) and endocrinologists in real-life setting. It is anticipated that patient recruitment will last 8 months (from Q3 2017 to Q1 2018) and each patient will be followed during the second visit 6±3 months later after the first visit. There are 2 time points:
- Baseline data: baseline data are defined as data available within 3 months prior to the first dose of dapagliflozin. In case of presence of multiple data values within baseline period the most recent pre-dose value will be selected
- Follow-up data: any post-baseline data will be considered as follow-up but the primary analysis will be focused on data available at 6±3 months after the first visit. In case of discontinuation dapagliflozin, data will be collected at routine visit within 3-month time frame after the last dose
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Study design:
This is a multi-centre observational, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with T2DM initiated with dapagliflozin by GPs and endocrinologists in real-life setting.
Only patients, who provide written consent to participate in the study will be enrolled into this study. All patients will be unique with no overlap between endocrinologists and GPs. All consecutive patients managed by GPs or endocrinologists who meet inclusion criteria will be included. All GPs and endocrinologists, who manage T2DM on sites, will be participating investigators.
Patients will undergo clinical assessment and receive the standard medical care as usual determined by the treating doctor based on their clinical judgement and national guidelines. Patients will not receive experimental treatment as a consequence of their participation in the observational study.
It is anticipated that patient recruitment will last for 8 months (from Q3 2017 to Q1 2018) and each patient will be followed during the second visit 6±3 months later after the first visit.
There are 2 time points:
- Baseline data: baseline data are defined as data available within 3 months prior to the first dose of dapagliflozin. In case of presence of multiple data values within baseline period the most recent pre-dose value will be selected
- Follow-up data: any post-baseline data will be considered as follow-up but the primary analysis will be focused on data available at 6±3 months after the first visit. In case of discontinuation dapagliflozin, data will be collected at routine visit within 3-month time frame after the last dose.
Data Source(s):
Baseline data will be collected during Visit 1 from the T2DM patient medical records, including disease history of patient, and during follow-up data during Visit 2 (after 6±3 months from Visit 1).
Study Population:
It is planned to include 900 male and female T2DM outpatients 18 years and older, who were managed by GPs or endocrinologists in 45 outpatient sites.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Belgorod Region, Shebekino, Federazione Russa, D1690R00037
- Research Site
-
Belgorod Region, Volokonovsky R-n, P. Volokonovka, Federazione Russa, D1690R00037
- Research Site
-
Gis-Khrustalny, Federazione Russa, D1690R00037
- Research Site
-
Izhevsk, Federazione Russa, D1690R00037
- Research Site
-
Kazan, Federazione Russa, D1690R00037
- Research Site
-
Lipetsk, Federazione Russa, D1690R00037
- Research Site
-
N. Novgorod, Federazione Russa, D1690R00037
- Research Site
-
N. Novgorod Region, Federazione Russa, D1690R00037
- Research Site
-
Novomoskovsk, Federazione Russa, D1690R00037
- Research Site
-
Novosibirsk, Federazione Russa, D1690R00037
- Research Site
-
Perm, Federazione Russa, D1690R00037
- Research Site
-
Ryazan, Federazione Russa, D1690R00037
- Research Site
-
Samara, Federazione Russa, D1690R00037
- Research Site
-
St-petersburg, Federazione Russa, D1690R00037
- Research Site
-
Tambov Region, Federazione Russa, D1690R00037
- Research Site
-
Volzhsk, Federazione Russa, D1690R00037
- Research Site
-
Voronezh, Federazione Russa, D1690R00037
- Research Site
-
Voronezh Region, Novovoronezh, Federazione Russa, D1690R00037
- Research Site
-
Yaroslavl, Federazione Russa, D1690R00037
- Research Site
-
Yoshkar-Ola, Federazione Russa, D1690R00037
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age 18 and older;
- Established diagnosis of T2DM (ICD-10 code E11.2-E11.9)
- The current treatment with dapagliflozin prescribed at least 1 month before the FSI;
- Written voluntary informed consent has been provided
- Management in outpatient setting.
Exclusion Criteria:
- Type 1 diabetes
- Current participation in a clinical trial
- Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
- Presence of serious/severe co-morbidities in the opinion of the investigator, which may limit treatment approach as usual.
- Treatment with drugs affecting glucose homeostasis (e.g., systemic glucocorticosteroids) within 3 months before to the 1st Visit
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Demographic parameters before dapagliflozin initiation in T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
mean age
|
3 months before dapagliflozin initiation
|
|
demographic characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
age distribution
|
3 months before dapagliflozin initiation
|
|
demographic characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
gender distribution
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
mean duration of T2DM
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
HbA1c (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
Weight (mean)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
SBP (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
DBP (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
Proportion of T2DM patients with diabetic complications
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
Proportion of patients with T2DM treatment intensification during 3 months before inclusion in the study
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
Proportion of patients with different treatment regimen
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
Proportion of patients on treatment with different classes of antidiabetic therapy
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
Lasso di tempo: 3 months before dapagliflozin initiation
|
Proportion of patients on different classes of concomitant therapy
|
3 months before dapagliflozin initiation
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Vladimir Bulatov, MD, PhD, AstraZeneca Russia
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- D1690R00037
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .